Encouraging OS results in neuroendocrine prostate cancer at #ESMO26!
#KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone.
• mOS: 10.2 vs 7.1 months (HR 0.33)
• rPFS: 5.1 vs 4.0 months (HR 0.66)
• PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16)
No new safety signals observed.
@myESMO @oncoalert
3983 views · 75 likes · 31 reposts · 2 replies
Updated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.org- David Einstein@davidjeinstein
@DrChoueiri @Dr_Aggen Strange results… 1 month PFS but 3 months OS benefit in a rapidly progressive disease… immediate separation of OS curves…
- Santhosh Ambika@RenoHemonc
@DrChoueiri @urotoday DLL3 regimens like Tarla should be the focus in these..
Source: Toni Choueiri, MD · x.com